Rizwan Haq, MD, PhD
"For me, research is about expanding knowledge that leads into action. Only though this combination of knowledge and practice can we make a difference in the lives of patients with melanoma and other cancers."
Dr. Haq is a graduate of the University of Toronto, where he completed his B.Sc. (Hon), and MD/PhD. His PhD was at the Ontario Cancer Institute/Princess Margaret Hospital in the laboratory of Dr. Brent Zanke. He completed his clinical training in internal medicine at The Johns Hopkins Hospital in Baltimore, followed by medical oncology training at Dana-Farber Cancer Institute and Massachusetts General Hospital. He joined the laboratory of Dr. David E. Fisher, where he conducted translational work in the melanoma; and was an attending oncologist at Massachusetts General Hospital.
He was recruited back to Dana-Farber Cancer Institute in 2014. His research focuses on resistance to melanoma therapies, including targeted agents and immunotherapies. He has been a contributing author of numerous high profile publications, including those published in Cancer Cell, Nature, Proceedings of the National Academy of Sciences USA. At Dana-Farber Cancer Institute, Dr. Haq devotes part of his time to developing the next generation of melanoma therapeutics and translating them to innovative investigator-initiated clinical trials. His clinical practice is dedicated to patients with melanoma.
Dr. Haq is a two-time MRA-funded investigator
Without you, melanoma research can't happen. Learn more about clinical trials.
Please support MRA's mission to end death and suffering due to melanoma. 100% of your donation will go directly to funding innovative melanoma research, without any overhead, admin, or fundraising expenses.